-

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at the Bank of America Securities Healthcare Conference 2026 on Thursday, May 14, 2026.

The company will take part in a fireside chat beginning at 8:40 a.m. PT/11:40 a.m. ET.

Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

corporatefinancial-news

Contacts

Media:
media@bms.com

Investors:
investor.relations@bms.com

Industry:

Bristol Myers Squibb

NYSE:BMY
Release Summary
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
Release Versions
English

Contacts

Media:
media@bms.com

Investors:
investor.relations@bms.com

More News From Bristol Myers Squibb

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

PRINCETON, N.J.--(BUSINESS WIRE)--Mariska Hargitay Partners with BMS for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease...

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival.......

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

PRINCETON, N.J.--(BUSINESS WIRE)--US FDA Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos to Treat Adolescents with oHCM...
Back to Newsroom